Dashboard
Manage Tickers

AIM AIM ImmunoTech Inc.

NYSE aimimmuno.com


$ 0.21 $ 0.00 (0.93 %)    

Friday, 06-Dec-2024 15:59:09 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 525.87 $ 4.67 (0.89 %)
DIA $ 447.30 $ -1.52 (-0.34 %)
SPY $ 607.78 $ 1.15 (0.19 %)
TLT $ 94.35 $ 0.14 (0.15 %)
GLD $ 242.95 $ 0.09 (0.04 %)
$ 0.207
$ 0.21
$ 0.00 x 0
$ 0.21 x 100
-- - --
$ 0.16 - $ 0.62
110,089
na
13.19M
$ -0.19
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-14-2024 09-30-2024 10-Q
2 08-14-2024 06-30-2024 10-Q
3 05-15-2024 03-31-2024 10-Q
4 03-30-2024 12-31-2023 10-K
5 11-14-2023 09-30-2023 10-Q
6 08-14-2023 06-30-2023 10-Q
7 05-15-2023 03-31-2023 10-Q
8 03-31-2023 12-31-2022 10-K
9 11-14-2022 09-30-2022 10-Q
10 08-15-2022 06-30-2022 10-Q
11 05-13-2022 03-31-2022 10-Q
12 03-31-2022 12-31-2021 10-K
13 11-15-2021 09-30-2021 10-Q
14 08-16-2021 06-30-2021 10-Q
15 05-17-2021 03-31-2021 10-Q
16 03-31-2021 12-31-2020 10-K
17 11-12-2020 09-30-2020 10-Q
18 08-14-2020 06-30-2020 10-Q
19 05-14-2020 03-31-2020 10-Q
20 03-30-2020 12-31-2019 10-K
21 11-14-2019 09-30-2019 10-Q
22 08-14-2019 06-30-2019 10-Q
23 05-15-2019 03-31-2019 10-Q
24 04-01-2019 12-31-2018 10-K
25 11-14-2018 09-30-2018 10-Q
26 08-14-2018 06-30-2018 10-Q
27 05-15-2018 03-31-2018 10-Q
28 03-30-2018 12-31-2017 10-K
29 11-14-2017 09-30-2017 10-Q
30 08-14-2017 06-30-2017 10-Q
31 05-15-2017 03-31-2017 10-Q
32 03-31-2017 12-31-2016 10-K
33 11-14-2016 09-30-2016 10-Q
34 08-15-2016 06-30-2016 10-Q
35 05-16-2016 03-31-2016 10-Q
36 03-29-2016 12-31-2015 10-K
37 11-16-2015 09-30-2015 10-Q
38 08-12-2015 06-30-2015 10-Q
39 05-12-2015 03-31-2015 10-Q
40 03-19-2015 12-31-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell-iss-finds-that-activist-groups-plan-is-limited-and-does-not-justify-control-of-the-board
ISS Recommends AIM ImmunoTech Shareholders...
12/05/2024 14:11:53

ISS Finds That Activist Group's Plan is "Limited" and Does Not Justify Control of the BoardISS Notes Activist Group...

kellner-group-urges-stockholders-of-aim-immunotech-to-vote-the-gold-card-says-kellner-group-has-financial-resources-aim-needs-kellner-group-owns-504-of-outstanding-shares-and-is-fully-aligned-with-stockholders
Kellner Group Urges Stockholders Of AIM Im...
12/02/2024 14:11:05

Kellner Group Has Financial Resources AIM NeedsKellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockho...

aim-immunotech-issues-presentation-detailing-why-shareholders-should-not-elect-activist-groups-nominees-to-the-board-highlights-activist-groups-nominees-checkered-backgrounds-skewed-incentives-and-lack-of-independence
AIM ImmunoTech Issues Presentation Detaili...
12/02/2024 14:04:03

Highlights Activist Group's Nominees' Checkered Backgrounds, Skewed Incentives and Lack of IndependenceWarns AIM Shareh...

aim-immunotech-refutes-activist-groups-false-and-misleading-claims-urges-shareholders-to-safeguard-aim-by-voting-for-all-of-the-boards-incumbent-candidates-and-discarding-any-proxy-materials-received-from-the-activist-group
AIM ImmunoTech Refutes Activist Group's Fa...
11/27/2024 20:31:57

Sets Record Straight on Mischaracterization of AIM's Historical Share PriceReminds AIM Shareholders of Activist Group's...

aim-immunotech-announced-cash-conservation-plan-independent-board-members-to-receive-100-of-director-compensation-in-aim-stock
Aim Immunotech Announced Cash Conservation...
11/27/2024 13:02:40

aim-immunotech-issues-presentation-detailing-case-for-re-electing-current-directors-to-oversee-continued-momentum-and-drive-strategy-to-create-long-term-value-for-patients-and-shareholders-warns-shareholders-of-its-belief-that-the-activist-group-and-its-nominees-have-a-self-interested-agenda-and-could-put-aims-clinical-progress-at-risk
AIM ImmunoTech Issues Presentation Detaili...
11/25/2024 13:18:15

Highlights How Positive Data in AIM's Clinical Pipeline and Big Pharma Partnerships are Positioning the Company for Commerc...

sec-form-4-filing-shows-aim-immunotech-ceo-and-director-thomas-k-equels-purchases-85000-shares-at-an-average-price-of-020
SEC Form 4 Filing Shows AIM ImmunoTech CEO...
11/21/2024 17:05:43

aim-immunotech-form4-filing-shows-ceo-and-president-thomas-k-equels-bought-60110-shares-at-an-average-price-of-018share
AIM ImmunoTech Form4 Filing Shows CEO And ...
11/20/2024 17:55:23

- SEC Filing 

aim-immunotech-shares-are-trading-higher-after-the-company-announced-the-publication-of-phase-1-data-from-its-roswell-park-study-on-ampligen-in-early-stage-triple-negative-breast-cancer
AIM ImmunoTech shares are trading higher a...
11/19/2024 13:04:10

aim-immunotech-announces-publication-of-phase-1-data-from-roswell-park-study-on-ampligen-in-early-stage-triple-negative-breast-cancer-in-the-journal-for-immunotherapy-of-cancer
AIM ImmunoTech Announces Publication Of Ph...
11/19/2024 13:02:29

roswell-parks-phase-1-trial-results-for-triple-negative-breast-cancer-with-66-achieving-complete-or-near-complete-remission-and-no-immune-related-adverse-events-findings-published-in-journal-for-immunotherapy-of-cancer
Roswell Park's Phase 1 Trial Results For T...
11/18/2024 18:16:28

https://www.roswellpark.org/newsroom/202411-roswell-park-clinical-trial-points-toward-promising-new-therapy-most-aggressive

aim-immunotech-shares-are-trading-higher-after-the-company-reported-better-than-expected-q3-eps-results
AIM ImmunoTech shares are trading higher a...
11/15/2024 13:31:42

aim-immunotech-q3-2024-gaap-eps-006-beats-012-estimate-sales-3500k-miss-6750k-estimate
AIM ImmunoTech Q3 2024 GAAP EPS $(0.06) Be...
11/15/2024 12:33:05

AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.12) b...

earnings-scheduled-for-november-15-2024
Earnings Scheduled For November 15, 2024
11/15/2024 08:32:08

insights-into-aim-immunotechs-upcoming-earnings
Insights into AIM ImmunoTech's Upcoming Ea...
11/14/2024 14:00:52

exploring-aim-immunotechs-earnings-expectations
Exploring AIM ImmunoTech's Earnings Expect...
11/07/2024 18:03:16

aim-immunotech-files-definitive-proxy-statement-and-sends-letter-to-shareholders-warns-shareholders-that-activist-groups-self-interested-agenda-could-disrupt-aims-momentum-and-destroy-chances-for-near-term-value-creation
AIM ImmunoTech Files Definitive Proxy Stat...
11/04/2024 13:10:26

Warns Shareholders that Activist Group's Self-Interested Agenda Could Disrupt AIM's Momentum and Destroy Chances for Ne...

maxim-group-maintains-buy-on-aim-immunotech-lowers-price-target-to-1
Maxim Group Maintains Buy on AIM ImmunoTec...
10/22/2024 21:29:26

Maxim Group analyst Jason McCarthy maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $2 to $1.

12-health-care-stocks-moving-in-thursdays-after-market-session
12 Health Care Stocks Moving In Thursday's...
10/03/2024 20:31:12

aim-immunotech-shares-are-trading-higher-after-the-company-announced-it-was-granted-us-patent-no-12102649-for-ampligen-for-the-treatment-of-endometriosis
AIM ImmunoTech shares are trading higher a...
10/03/2024 12:48:02

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION